CN1857725A - Slow released compound antituberculotic preparation containing synergist - Google Patents
Slow released compound antituberculotic preparation containing synergist Download PDFInfo
- Publication number
- CN1857725A CN1857725A CNA2006102003372A CN200610200337A CN1857725A CN 1857725 A CN1857725 A CN 1857725A CN A2006102003372 A CNA2006102003372 A CN A2006102003372A CN 200610200337 A CN200610200337 A CN 200610200337A CN 1857725 A CN1857725 A CN 1857725A
- Authority
- CN
- China
- Prior art keywords
- combination
- ofloxacin
- capreomycin
- slow
- tuberculosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The slow released compound antituberculotic preparation containing synergist is implanting agent or slow released injection comprising slow released microsphere and solvent. The slow released microsphere consists of slow releasing supplementary material, at least one antituberculotic selected from rifampicin, isoniazid and pyrazinamide and at least one antituberculotic synergist selected from cycloserine, ofloxacin, ciprofloxacin, sparfloxacin and capreomycin. The solvent is special solvent containing suspending agent carboxymethyl cellulose, etc. and with viscosity of 100-3000 cp at 20-30 deg.c. The slow releasing supplementary material is selected from EVAc, PLA, PLGA, etc. The slow released compound antituberculotic preparation can release antituberculotic in the local tubercolosis part for 30-40 days so as to maintain the local effective medicine concentration while lowering systemic toxicity. The present invention has obvious unique treating effect on various kinds of intractable tuberulosis.
Description
(1) technical field
The present invention relates to a kind of slow released compound antituberculotic preparation, belong to technical field of pharmaceuticals.Particularly, the invention provides a kind of slow releasing preparation that contains the compound antituberculotic of synergist, be mainly slow releasing injection and sustained-release implant.This slow releasing agent topical application is main, can and keep active drug concentration in the local acquisition of tuberculose focus.
(2) background technology
The tuberculosis that with the pulmonary tuberculosis is representative was exactly a kind of disease that has a strong impact on people ' s health originally, was widely current in the whole world, had seized several hundred million people's life, and people are referred to as white pestilence, and saying of " ten consumptive diseases nine being dead " once arranged.Along with the appearance of antituberculosis drugses such as streptomycin and isoniazid, tuberculosis has become a kind of medicable disease.Yet along with people to the ignorance of its seriousness, it is relevant that to prevent and treat the obvious deficiency, the treatment that drop into the aspect lack of standardization, the drug-fast generation of the tulase that causes has thus become successfully treats this sick most thorny issue.
Because its infectiousness is very strong, the annual in recent years whole world of its sickness rate is increasing with 1% speed.Need in three kinds of diseases of emphasis control in the whole world that World Health Organization (WHO) determines, tuberculosis is only second to acquired immune deficiency syndrome (AIDS), occupies before the malaria.The whole world promptly has a people to be subjected to tubercle bacillus affection the each second, and per minute has 3 to 4 people because of tuberculosis death, and the whole world 3,000,000 people that still have an appointment every year on average die from tuberculosis at present.The tuberculosis of China is at present popular very serious, has now become one of 22 the high burden of tuberculosis countries in the world; China has 6,000,000 tuberculosis patients approximately at present, accounts for 1/3rd of global number of patients, occupies the second place of the world and is only second to India; Accounted for 1/4th of the whole world Chinese drug resistance patient.The whole nation has at least 1,500,000 routine new patients take place every year, and wherein the infectiousness patient surpasses 650,000 examples, and annual number because of tuberculosis death is up to 250,000, and mostly is young and middle-aged.It has become No.1 killer as single infectious disease.Tuberculosis needs the continuous use more than six months just can obtain satisfied prognosis.Because treatment time is longer, many patients may just forget in time quantitatively to take medicine, thereby often cause chemical sproof generation.And drug-resistant tuberculosis people's treatment is spinning out of time on the one hand, is exactly multiple medication combined chemotherapy application charges costliness on the other hand.As needing more than 10,000 yuan in China.Therefore, research and develop the world subject that new effectively preventing preparation lungy or method have become eager solution.
At present, there are many new antituberculotics to demonstrate curative effect preferably, however not ideal enough to anti-multiple medicines tuberculosis (MDR-TB) effect.Because to a lot of chronic lesions, particularly local lesion, the routine treatment administration is difficult to obtain effective bacteriocidal concentration.Escalated dose or take medicine for a long time and have a lot of side effect again.
(3) summary of the invention
The present invention is directed to the deficiencies in the prior art, a kind of slow releasing preparation that contains the compound anti-tuberculosis medicine is provided, particularly, is a kind of slow releasing injection and sustained-release implant that contains synergist.
Anti-tuberculosis drugs is mainly oral formulations, can not obtain active drug concentration in lesions position.Even general injection is also not ideal enough.Because dose deficiency, single drug, irregular factor such as take medicine not only can not reach effective blood concentration, are not enough to thoroughly kill tulase, and lure that fastbacteria survives or impel the tulase variation into.Depending merely on increases the restriction that dosage can be subjected to general toxic reaction again.The generation of anti-multiple medicines tuberculosis (MDR-TB) has greatly limited the application of medicine.
Anti-multiple medicines tuberculosis (MDR-TB) is meant tulase anti-isoniazid (INH) and rifampicin (RFP) person at least simultaneously, and the treatment of MDR-TB has become problem anxious to be solved in the tuberculosis control work.So far, antituberculotics still is at a loss what to do to anti-multiple medicines tulase.
The present invention finds, the compound anti-tuberculosis medicine that will contain synergist makes that slow releasing agent (being mainly slow releasing injection and sustained-release implant) is local to be placed or injection not only can greatly improve partial drug level, reduces the concentration of medicine in blood circulation, reduce the toxicity of medicine to normal structure, can also greatly make things convenient for medicinal application, reduce the course of treatment, shorten treatment time, reduce medicine complication, reduce patient expense, reduce the single medicine consumption, strengthen therapeutic effect, reduce drug resistance.The therapeutic effect that anti-multiple medicines tuberculosis and tuberculosis local lesion are had remarkable uniqueness.
With the tuberculous cavity is example, because the barrier action of tuberculous cavity wall, hole wall peripheral vessels rareness, sclerosis even closure in addition are difficult to infiltrate in the cavity through the antituberculotics of conventional approach (oral or intramuscular injection or drop) application.Drug level in the cavity is very low, does not have sterilization or bacteriostasis, causes that on the contrary the drug resistance tulase produces.Placement of percutaneous lung puncture or injection slow releasing pharmaceutical not only can inject medicine in the cavity more exactly under iconography technology such as ultrasound wave and/or CT help, also can medicine be confined to tens of skies in the wall of hole, thereby directly effectively kill the tulase in the wall of hole by release mechanism; In addition, caseous focus is softening, sphacelus comes off discharge because the medicine that discharges to the corrosion function of hole wall, can impel; During partial operation also can by means of puncture needle or corresponding utensil (as but be not limited to bronchoscope, cystoscope, peritoneoscope, articular cavity mirror etc.) local kitchen range is removed.Moreover, local repeated multiple times puncture also can weaken the barrier action of empty wall.So the medicine that not only helps in the blood enters focus, also helps the hypertrophy of granulation tissue and the purification in cavity.The medicine of different mechanism of action, medication combined (synthetic medication combined with inhibition RNA as suppressing the synthetic medicine of the DNA) application that particularly contains synergist has also greatly strengthened the sensitivity of antibacterial.And reduced the application dose of single medicine, thereby reduce side effects of pharmaceutical drugs dramatically.The above unexpected main contents of the present invention of finding to constitute.
A kind of form of medicinal slow release agent of the present invention is a slow releasing injection, is made up of sustained-release micro-spheres and solvent.Particularly, this slow releasing injection is grouped into by following one-tenth:
(a) sustained-release microparticle, the one-tenth following by percentage by weight is grouped into:
The sick effective ingredient 1-70% of tuberculosis
Slow-release auxiliary material 30-99%
Suspending agent 0.0-30%
More than be weight percentage
With
(b) solvent is for common solvent or contain the special solvent of suspending agent.
Wherein,
Slow-release auxiliary material is selected from one of copolymer (PLGA), xylitol, oligosaccharide, chrondroitin, chitin, hyaluronic acid, collagen protein, gelatin and white tempera of polifeprosan, bis-fatty acid and decanedioic acid copolymer (PFAD-SA), poly-(erucic acid dimer-decanedioic acid) [P (EAD-SA)], poly-(fumaric acid-decanedioic acid) [P (FA-SA)], ethylene vinyl acetate copolymer (EVAc), polylactic acid (PLA), polyglycolic acid and hydroxyacetic acid or its combination; Suspending agent is selected from one of sodium carboxymethyl cellulose, (iodine) glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, soil temperature 20, soil temperature 40 and soil temperature 80 or its combination.
The sick effective ingredient of tuberculosis is anti-tuberculosis drugs and anti-tuberculosis drugs synergist.
The available anti-tuberculosis drugs of the present invention is following a kind of or its combination: rifampicin, rifamycin (rifamycin), rifapentine (rifapentine, DL473, rifapentine), (the sharp good fortune of spirocyclic piperidine is mould to utilize the cloth spit of fland, ansamycin, LM427), isoniazid (isoniazid), pyrazinamide (pyrazinamide), ethambutol (ethambutol), sodium aminosalicylate (sodium para-aminosal icylate), streptomycin (streptomycin), kanamycin, amikacin, amikacin (AMK), ethionamide, prothionamide.
The anti-tuberculosis drugs synergist is a kind of or its combination in cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin, the capreomycin.
The effective ingredient of medicinal slow release agent of the present invention is above-mentioned any one or more than one anti-tuberculosis drugs and any one or or the combination of more than one two kinds of anti-tuberculosis drugs synergists.
Preferred combination also can be:
(a) rifampicin and or the combination of isoniazid and cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin;
(b) combination of streptomycin, kanamycin, amikacin or amikacin and cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin;
(c) combination of pyrazinamide, ethambutol or sodium aminosalicylate and cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin;
(d) combination of rifampicin and pyrazinamide and cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin;
(e) the different combination with cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin of ethionamide or rosickyite;
(f) rifamycin, rifapentine or utilize the different combination in cloth spit of fland and ethionamide or rosickyite; Or
(g) combination of isoniazid and pyrazinamide and cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin.
Wherein most preferred being combined as: the combination of rifampicin and pyrazinamide and isoniazid and cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin.
The sick effective ingredient of above-mentioned tuberculosis shared ratio in slow releasing agent is decided because of concrete condition, can be 1%-70%, is good with 2%-50%, and 5%-40% is best.The weight ratio of anti-tuberculosis drugs and anti-tuberculosis drugs synergist is 1: 9 to 9: 1.
The effective ingredient in the tuberculosis sustained-release micro-spheres of the present invention and the percentage by weight of slow-release auxiliary material are preferably as follows:
The sick effective ingredient 2-50% of tuberculosis
Slow-release auxiliary material 50-98%
Suspending agent 0.0-30%
Slow-release auxiliary material is selected from copolymer, hyaluronic acid, collagen protein or the gelatin of polifeprosan, bis-fatty acid and decanedioic acid copolymer (PFAD-SA), poly-(erucic acid dimer-decanedioic acid), poly-(fumaric acid-decanedioic acid), ethylene vinyl acetate copolymer, polylactic acid, polyglycolic acid and hydroxyacetic acid.
Slow-release auxiliary material and percentage by weight thereof are most preferably as follows in the sustained-release micro-spheres of the present invention:
(1) PLA of 55-90%;
(2) PLGA of 50-90%;
(3) polifeprosan of 50-85%;
(4) bis-fatty acid of 55-90% and decanedioic acid copolymer; Or
(5) EVAc of 55-90%.
Above sustained-release micro-spheres is made slow releasing injection with the solvent that contains sodium carboxymethyl cellulose, (iodine) glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, soil temperature 20, soil temperature 40 or soil temperature 80 suspending agents.Wherein the concentration of sodium carboxymethyl cellulose in solvent can be 0.1-5%, but is preferred with 0.5-3%, with 1-2% for most preferably.
The molecular weight peak value of polylactic acid can be, but is not limited to, 5000-100, and 000, but with 20,000-60,000 is preferred, with 30,000-50,000 for most preferably; The molecular weight of polyglycolic acid can be, but is not limited to, 5000-100, and 000, but with 20,000-60,000 is preferred, with 30,000-50,000 for most preferably; Above polyhydroxy acid can singly select or multiselect.When singly selecting, serve as preferred with the copolymer (PLGA) of polylactic acid (PLA) or hydroxy carboxylic acid and glycolic, the molecular weight of copolymer can be, but is not limited to, 5000-100,000, but with 20,000-60,000 be preferably, with 30,000-50,000 for most preferably; When multiselect, compound polymer or the copolymer formed with macromolecule polymer or different macromolecule polymer serve as preferred, with the compound polymer that contains different molecular weight polylactic acid or decanedioic acid or copolymer for most preferably, as, but be not limited to, molecular weight is 1000 to 30000 polylactic acid with molecular weight is that 20000 to 50000 polylactic acid mixes, molecular weight is 10000 to 30000 polylactic acid with molecular weight is that 30000 to 80000 PLGA mixes, molecular weight is that 20000 to 30000 polylactic acid mixes with decanedioic acid, molecular weight is that 30000 to 80000 PLGA mixes with decanedioic acid.
In various high molecular polymers, with polylactic acid, decanedioic acid, the mixture or the copolymer that contain the macromolecule polymer of polylactic acid or certain herbaceous plants with big flowers diacid is first-selection, mixture and copolymer can be selected from, but be not limited to the mixture or the copolymer of the mixture of PLA, PLGA, glycolic and hydroxy carboxylic acid, certain herbaceous plants with big flowers diacid and fragrant polyanhydride or aliphatic polyanhydride.The blend ratio of glycolic and hydroxy carboxylic acid is 10/90-90/10 (weight), preferably 25/75-75/25 (weight).The method of blend is arbitrarily.Content when glycolic and hydroxy carboxylic acid copolymerization is respectively percentage by weight 10-90% and 90-10%.The representative of fragrance polyanhydride is polifeprosan [poly-(1,3-two (to the carboxyl phenoxy group) propane-decanedioic acid) (p (CPP-SA)), bis-fatty acid-decanedioic acid copolymer (PFAD-SA)], poly-(erucic acid dimer-decanedioic acid) [P (EAD-SA)] and poly-(fumaric acid-decanedioic acid) [P (FA-SA)] etc.Content during to carboxylic phenoxypropane (p-CPP) and decanedioic acid copolymerization is respectively percentage by weight 10-60% and 20-90%, and the blend weight ratio is 10-40: 50-90, preferably weight ratio 15-30: 65-85.
Except that above-mentioned adjuvant, also can select for use other materials to see the United States Patent (USP) (patent No. 4757128; 4857311; 4888176; 4789724) and in " pharmaceutic adjuvant complete works " (the 123rd page, Sichuan science tech publishing house published in 1993, Luo Mingsheng and Gao Tianhui chief editor) have a detailed description.In addition, Chinese patent (application number 96115937.5; 91109723.6; 9710703.3; 01803562.0) and U.S.'s patent of invention (patent No. 5,651,986) also enumerated some pharmaceutic adjuvant, comprise filler, solubilizing agent, absorption enhancer, film former, gellant, system (or causing) hole agent, excipient or blocker etc.
For regulating drug releasing rate or changing other characteristic of the present invention, can change the composition and the proportioning of monomer component or molecular weight, interpolation or the adjusting pharmaceutic adjuvant of polymer, add the water-soluble low-molecular chemical compound, as, but be not limited to various sugar or salt etc.Wherein sugar can be, but is not limited to, xylitol, oligosaccharide, (sulphuric acid) chrondroitin and chitin etc., and wherein salt can be, but is not limited to, potassium salt and sodium salt etc.
In the slow releasing injection, drug sustained release system can be made into microsphere, sub-micro ball, microemulsion, nanosphere, granule or spherical piller, makes the injection use then with after the injection solvent mixes.In various slow releasing injection, serve as preferred with the suspension type slow releasing injection, the suspension type slow releasing injection is the preparation that the drug sustained release system that will contain the tuberculosis composition is suspended in gained in the injection, used adjuvant is a kind of or its combination in the above-mentioned slow-release auxiliary material, and used solvent is common solvent or the special solvent that contains suspending agent.Common solvent is, but is not limited to the buffer that distilled water, water for injection, physiology are prepared towards liquid, dehydrated alcohol or various salt.The purpose of suspending agent is the pastille microsphere that effectively suspends, thereby is beneficial to the usefulness of injection.
Suspending agent is selected from one of sodium carboxymethyl cellulose, (iodine) glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, soil temperature 20, soil temperature 40 and soil temperature 80 or its combination.
The content of suspending agent in common solvent is decided because of its characteristic, can be 0.1-30% and decides because of concrete condition.Consisting of of preferred suspending agent:
A) 0.5-5% sodium carboxymethyl cellulose+0.1-0.5% soil temperature 80; Or
B) 5-20% mannitol+0.1-0.5% soil temperature 80; Or.
C) 0.5-5% sodium carboxymethyl cellulose+5-20% sorbitol+0.1-0.5% soil temperature 80.
The preparation method of slow releasing injection is arbitrarily, available some kinds of methods preparation: as, but be not limited to, mixing method, fusion method, dissolution method, spray drying method for preparation microsphere, dissolution method are made micropowder, liposome bag medicine method and emulsion process etc. in conjunction with freezing (drying) comminuting method.Serve as preferred wherein with dissolution method (being the solvent volatility process), seasoning, spray drying method and emulsion process.Microsphere then can be used for preparing above-mentioned various slow releasing injection, and its method is arbitrarily.The particle size range of used microsphere can be between 5-400um, serving as preferred between the 10-300um, with between the 20-200um for most preferably.
Microsphere also can be used for preparing other slow releasing injection, as gel injection, gel rubber sustained-release injection, block copolymer micelle injection.Wherein, block copolymer micelle is formed in aqueous solution by hydrophobic-hydrophilic block copolymers, has spherical inner core-shell mechanism, and hydrophobic block forms kernel, and hydrophilic block forms shell.The carrier micelle injection enters the purpose that reaches control drug release or targeted therapy in the body.Used pharmaceutical carrier is above-mentioned any one or its combination.Wherein preferred molecular weight is the hydrophilic block of the Polyethylene Glycol (PEG) of 1000-15000 as the micelle copolymer, and preferred biological degradation polyalcohol (as PLA, polylactide, polycaprolactone and copolymer thereof (molecular weight 1500-25000)) is as the hydrophobic block of micelle copolymer.The particle size range of block copolymer micelle can be between 10-300um, between the 20-200um serving as preferred.Gel injection system is dissolved in some amphipathic solvent with biological degradation polyalcohol (as PLA, PLGA or DL-LA and epsilon-caprolactone copolymer), adds medicine miscible with it (or suspendible) back again and forms flowability gel preferably, can be through local injection.In case inject, amphipathic solvent diffuses to body fluid very soon, the moisture in the body fluid then infiltrates gel, makes polymer cure, slowly discharges medicine.
The present invention finds to influence medicine and/or sustained-release micro-spheres suspends and/or the key factor of injection is the viscosity of solvent, and viscosity is big more, and suspension effect is good more, and syringeability is strong more.This unexpected one of main index characteristic of the present invention of finding to have constituted.The viscosity of solvent depends on the viscosity of suspending agent, and the viscosity of suspending agent is 100cp-3000cp (20 ℃-30 ℃ time), preferred 1000cp-3000cp (20 ℃-30 ℃ time), most preferably 1500cp-3000cp (20 ℃-30 ℃ time).According to the viscosity of the prepared solvent of this condition is 10cp-650cp (20 ℃-30 ℃ time), preferred 20cp-650cp (20 ℃-30 ℃ time), most preferably 60cp-650cp (20 ℃-30 ℃ time).
The preparation of injection has several different methods, and a kind of is that the sustained-release microparticle (A) of suspending agent for " 0 " directly mixed in special solvent, obtains corresponding sustained-release microparticle injection; Another kind is that suspending agent is not mixed in special solvent or common solvent for the sustained-release microparticle (A) of " 0 ", obtains corresponding sustained-release microparticle injection; Another is that sustained-release microparticle (A) is mixed in common solvent, adds the suspending agent mixing then, obtains corresponding sustained-release microparticle injection.Except, also can earlier sustained-release microparticle (A) be mixed and in special solvent, make corresponding suspension, with the moisture in ways such as the vacuum drying removal suspension, special solvent of reuse or common solvent suspendible obtain corresponding sustained-release microparticle injection afterwards then.Above method just is illustrative rather than definitive thereof the present invention.It should be noted that suspended drug or sustained-release micro-spheres (or microcapsule) concentration in injection decide because of specifically needing, can be, but be not limited to, 10-400mg/ml, but be preferably with 30-300mg/ml, with 50-200mg/ml most preferably.The viscosity of injection is 50cp-1000cp (20 ℃-30 ℃ time), preferred 100cp-1000cp (20 ℃-30 ℃ time), most preferably 200cp-650cp (20 ℃-30 ℃ time).This viscosity is applicable to 18-22 injection needle and special bigger (to 3 millimeters) injection needle of internal diameter.
Sustained-release micro-spheres also can be used for preparing sustained-release implant, used pharmaceutic adjuvant can be any or multiple material in the above-mentioned pharmaceutic adjuvant, but with the high molecular weight water soluble polymer is main separation, in various high molecular polymers, with polylactic acid, certain herbaceous plants with big flowers diacid, the mixture or the copolymer that contain the macromolecule polymer of polylactic acid or certain herbaceous plants with big flowers diacid is first-selection, mixture and copolymer can be selected from, but be not limited to the mixture or the copolymer of the mixture of PLA, PLGA, PLA and PLGA, certain herbaceous plants with big flowers diacid and fragrant polyanhydride or aliphatic polyanhydride.Polylactic acid (PLA) is 10/90-90/10 (weight) with the blend ratio of polyglycolic acid, preferably 25/75-75/25 (weight).The method of blend is arbitrarily.Content when glycolic and lactic acid copolymerization is respectively percentage by weight 10-90% and 90-10%.The representative of fragrance polyanhydride is to carboxy phenyl propane (p-CPP), content during to carboxy phenyl propane (p-CPP) and the copolymerization of certain herbaceous plants with big flowers diacid is respectively percentage by weight 10-60% and 20-90%, the blend weight ratio is 10-40: 50-90, preferably weight ratio 15-30: 65-85.
Therefore, another form of slow releasing agent of the present invention is that slow releasing agent is a sustained-release implant.The effective ingredient of tuberculosis implant can be packaged in the whole pharmaceutic adjuvant equably, also can be packaged in carrier holder center or its surface; Can effective ingredient be discharged by direct diffusion and/or the mode of degrading through polymer.
The characteristics of sustained-release implant are that used slow-release auxiliary material removes the high molecular polymerization beyond the region of objective existence, also contain above-mentioned any one or multiple other adjuvant.The pharmaceutic adjuvant that adds is referred to as additive.Additive can be divided into filler, porogen, excipient, dispersant, isotonic agent, preservative agent, blocker, solubilizing agent, absorption enhancer, film former, gellant etc. according to its function.
The Main Ingredients and Appearance of sustained-release implant can be made into multiple dosage form.As, but be not limited to capsule, slow releasing agent, implant, slow releasing agent implant etc.; Be multiple shape, as, but be not limited to granule, pill, tablet, powder, granule, sphere, bulk, needle-like, bar-shaped, column and membranaceous.In various dosage forms, serve as preferred slowly to discharge implant in the body.The volume size depends on factors such as the position, size of focus.Can be the bar-shaped of 0.1-5mm (slightly) * 1-10mm (length), also can be other shapes such as lamellar.
The most preferred dosage form of sustained-release implant is that the slow releasing agent that biocompatibility, degradable absorb is implanted, and can make different shape and various dosage form because of the clinical needs of difference.The packing method of its Main Ingredients and Appearance and step in United States Patent (USP) (US5651986) have a detailed description, comprise the some kinds of methods that prepare slow releasing preparation: as, but be not limited to, (i) carrier holder powder and medicament mixed be pressed into implant then, promptly so-called mixing method; (ii) carrier holder fusing, mix solid cooled then, promptly so-called fusion method mutually with medicine to be packaged; (iii) the carrier holder is dissolved in the solvent, medicine dissolution to be packaged or be scattered in the polymer solution, evaporating solvent then, drying, promptly so-called dissolution method; (iv) spray drying method; And (v) freeze-drying etc.
The effective ingredient and the percentage by weight of sustained-release implant of the present invention are preferably as follows:
Anti-tuberculosis drugs 2-50%
Slow-release auxiliary material 50-98%
Suspending agent 0.0-30%
Tuberculosis effective ingredient and percentage by weight thereof are preferably in the sustained-release implant of the present invention:
(a) rifampicin of 2-50%, rifamycin, rifapentine or utilize the combination of cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or the capreomycin of cloth spit of fland and 2-50%;
(b) combination of the cycloserine of the streptomycin of 2-50%, kanamycin, amikacin or amikacin and 2-50%, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin;
(c) combination of the cycloserine of the isoniazid of 2-50%, pyrazinamide, ethambutol or sodium aminosalicylate and 2-50%, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin;
(d) combination of the cycloserine of the rifampicin of 2-50% and pyrazinamide and 2-50%, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin;
(e) combination of different cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or the capreomycin with 2-50% of the ethionamide of 2-50% or rosickyite;
(f) combination of the cycloserine of the rifampicin of 2-50% and isoniazid and 2-50%, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin;
(g) combination of the isoniazid of the isoniazid of 2-50% and pyrazinamide and 2-50% and cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin; Or
(h) combination of the cycloserine of the isoniazid of the pyrazinamide of the isoniazid of 2-50% and 2-50% and 2-50% and 2-50%, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin.
Slow-release auxiliary material and percentage by weight thereof are most preferably as follows in the sustained-release implant of the present invention:
(1) PLA of 55-90%;
(2) PLGA of 50-90%;
(3) polifeprosan of 50-85%;
(4) bis-fatty acid of 55-90% and decanedioic acid copolymer; Or
(5) EVAc of 55-90%.
The percentage by weight of the slow-release auxiliary material in the tuberculosis sustained-release micro-spheres of the present invention is preferably as follows:
In addition, selected adjuvant also can be above-mentioned any one above combination.
The present invention can be used to prepare the pharmaceutical preparation of the various tuberculosis for the treatment of people and animal, is mainly slow releasing injection or sustained-release implant.Though the drug prepared preparation can be used for whole body tuberculosis such as phthisical treatment, local lesion serves as preferred with treatment.Common local lesion or be referred to as the outer tuberculosis of lung and mainly comprise: tuberculoma, lymphoid tuberculosis, tuberculosis of bone and joint, synovial tuberculosis, tuberculous osteomyelitis, renal tuberculosis, tuberculosis of skin, tuberculosis of intestine, tuberculosis of breast, genital tuberculosis (fallopian tube, endometrium, testis, epididymis), tuberculosis of anus, tuberculosis of thyroid gland, tuberculosis of pericardium, thoracic tuberculosis, tuberculosis fistula road, tuberculous pleuritis etc.In addition, local lesion also comprises chronic fibro cavernous pulmonary tuberculosis and the chronic pathological changes that causes because of tuberculosis or merge, as: but be not limited to serious symptom decubital ulcer, intractable cutaneous ulcer, diabetic foot, femur head necrosis and old prostate class disease etc.
Route of administration depends on multiple factor, for obtain valid density in position, tuberculosis place, medicine can give through number of ways, as in subcutaneous, intracavity (in abdominal cavity, thoracic cavity and canalis spinalis), focus week or intralesional injection or placement, the lymph node and injection in the bone marrow, but sustained-release implant is with focus local injection (slow releasing injection) or to place (sustained-release implant) serve as preferred.Can or place in when operation or perioperatively injection; Can be through apparatus interventional therapys such as fibre bronchus mirrors, as the treatment pulmonary tuberculosis cavity; But also percutaneous puncture intralesional administration interventional therapy; But also intraarticular injection or placement; Can separate application with systemic chemotherapy while or front and back, but the whole body antituberculosis therapy of a week to several months is preferably arranged before and after the topical application.
Drug dose is different different because of the medicine composition, does not wait but a medicine total amount can be 10% to 200% of conventional route day dosage.Wherein each dose is announced the up-to-date compatibility dosage requirement that is proposed with reference to WHO2001 number one (79 the 1st phase of volume).As cycloserine is 5～10 milligrams/kilogram; Ofloxacin is 7.5～15 milligrams/kilogram or 0.6-0.8g/d); Ciprofloxacin is 1.0-1.5g/d; 2～60 milligrams/kilogram of the whole body daily doses of pyrazinamide, ethambutol are 1.5～40 milligrams/kilogram; When two kinds of medication combined application, the dosage of each medicine surpasses 100% of its dosage conventional route day.The whole body daily dose of pyrazinamide is no more than 30 milligrams/kilogram, and ethambutol is no more than 20 milligrams/kilogram.If focus is not removed fully or improved, can consider to place once more after 20 to 40 days or the injection slow releasing agent.For preventing that the intralesional tulase from sending out, should be equipped with the whole body administration before and after each topical.
Also can add other medicinal ingredient in slow releasing injection that the present invention is made or the sustained-release implant, as, but be not limited to antibiotics, antalgica, anticoagulant medicine, hemorrhage etc.
By following test and embodiment technical method of the present invention is further described:
The local drug concentration that test 1, different modes are used behind the anti-tuberculosis drugs (rifampicin) compares
With the rat is subjects, will accept equivalent rifampicin (10 milligrams) through following different modes respectively after its grouping: group 1, the common rifampicin injection of lumbar injection; Group 2, the common rifampicin injection of hypochondrium subcutaneous injection; Group 3, hypochondrium subcutaneous injection rifampicin slow releasing injection; Group 4, hypochondrium subcutaneous placement rifampicin sustained-release implant.Measure topical place drug level after one week, two weeks, three weeks respectively.The result shows, the local drug concentration significant difference after different modes is used, and topical can obviously improve, and effectively keeps the active drug concentration of medicine-feeding part.It is best with the effect of injection slow releasing injection wherein to place sustained-release implant with the part.Yet, local injection slow releasing injection operation most convenient, easy.This discovery constitutes key character of the present invention.Following correlation test has further confirmed this point.
The interior bacteriostasis of body that test 2, different modes are used behind the anti-tuberculosis drugs compares
With the rat is subjects, with 2 * 10
5Individual tubercule bacillus is injected in its femur bone marrow intracavity, and the grouping (10/group) according to test 1 after the week awards the treatment of equivalent isoniazid.Check inflammatory activity such as local redness subsequently, put to death animal after 30 days and get local bone marrow inspection bacterium.The result shows that injection isoniazid slow releasing injection and placement isoniazid sustained-release implant group effect are best, and first week beginning after treatment of local redness is obviously dwindled, and all animals do not have death.In the common isoniazid injection of lumbar injection (i.p.) group, dead in 70% animal 20 days; In the common isoniazid injection of local injection group, dead in 20% animal 20 days, but dead in 70% animal 30 days.Relatively fungistatic effect shows, the difference between the effects after different modes is used is remarkable, and topical can obviously improve and effectively keep the active drug concentration at position, place, and it is best with the effect of injection slow releasing injection wherein to place sustained-release implant with the part.But, injection slow releasing injection operation most convenient, easy.Good effect not only, toxic and side effects is also little.
Above result shows, the anti-tuberculosis drugs isoniazid is through the bacteriostasis difference of different approaches administration, is (P＜0.01), wherein local injection isoniazid slow releasing injection and local better effects if of placing the isoniazid sustained-release implant well with the effect of topical application.
The vivo bacteria corrosion action of test 3, antituberculotics and synergist relatively
With the rat is subjects, with 2 * 10
5Individual tubercule bacillus is injected in its femur bone marrow intracavity, and week back grouping (10/group) also awards the sustained-release implant treatment that contains different pharmaceutical.Check inflammatory activity such as local redness subsequently, put to death animal after 30 days and get local bone marrow inspection bacterium.Result's (table 1) shows, isoniazid (10mg/kg), ofloxacin (5mg/kg) and the independent application of rifampicin (5mg/kg) implant all have certain controlling to imitate, first week beginning after treatment of local redness is obviously dwindled, the animal dead rate is respectively 50% and 60% in 60 days, mortality rate (%) only is that 10% to 20%, three kind of medication combined animal dead rate is 0 in the animal 60 days of the therapeutic alliance group behind the synergist yet add.
Table 1
| Test group (n) | Suffered treatment | Animal dead rate (%) | The P value |
| 1(10) | Contrast | 100 | |
| 2(10) | The isoniazid implant | 50 | ＜0.05 |
| 3(10) | The rifampicin implant | 60 | ＜0.05 |
| 4(10) | The ofloxacin implant | 40 | ＜0.05 |
| 5(10) | Rifampicin and ofloxacin implant | 20 | ＜0.01 |
| 6(10) | Isoniazid and ofloxacin implant | 10 | ＜0.01 |
| 7(10) | Rifampicin and isoniazid and ofloxacin implant | 0 | ＜0.001 |
Same potentiation also sees the combination that same potentiation also sees cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin and rifampicin, rifamycin, rifapentine, utilizes cloth spit of fland, isoniazid, pyrazinamide, ethambutol, sodium aminosalicylate, streptomycin, kanamycin, amikacin or amikacin.
Bacteriostasis relatively in the body of test 4, antituberculotics and synergist
With the rat is subjects, with 2 * 10
5Individual tubercule bacillus is injected in its femur bone marrow intracavity, and week back grouping (10/group) also awards the sustained-release implant treatment that contains different pharmaceutical.Check inflammatory activity such as local redness subsequently, put to death animal after 30 days and get local bone marrow inspection bacterium.The results are shown in Table 2
Table 2
| Test group (n) | Suffered treatment | Bacteriostasis rate (%) | The P value |
| 1(10) | Contrast | 0 | |
| 2(10) | The pyrazinamide implant | 30 | ＜0.05 |
| 3(10) | The rifapentine sustained-release implant | 40 | ＜0.05 |
| 4(10) | The capreomycin sustained-release implant | 40 | ＜0.05 |
| 5(10) | Pyrazinamide and capreomycin injection | 70 | ＜0.01 |
| 6(10) | Rifapentine and capreomycin implant | 70 | ＜0.01 |
| 7(10) | Rifapentine and pyrazinamide and capreomycin implant | 90 | ＜0.001 |
The result shows, pyrazinamide (5mg/kg), rifapentine (5mg/kg) and the independent placement of capreomycin implant all have certain fungistatic effect, bacteriostasis rate is 30% to 40%, yet, effect when share with synergist obviously strengthens, effect is best when share with pyrazinamide, rifapentine and capreomycin three medicines, and bacteriostasis rate is 90%.Operation most convenient, easy.Good effect not only, toxic and side effects is little.
Same potentiation also sees cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin and rifampicin, rifamycin, rifapentine, utilizes the combination of cloth spit of fland, pyrazinamide, ethambutol or sodium aminosalicylate.
Bacteriostasis relatively in the body of test 5, antituberculotics and synergist
With the rat is subjects, with 2 * 10
5Individual tubercule bacillus is injected in its femur bone marrow intracavity, and week back grouping (10/group) also awards the sustained-release implant treatment that contains different pharmaceutical.Check inflammatory activity such as local redness subsequently, put to death animal after 30 days and get local bone marrow inspection bacterium.The results are shown in Table 3
Table 3
| Test group (n) | Suffered treatment | Bacteriostasis rate (%) | The P value |
| 1(10) | Contrast | 0 | |
| 2(10) | The kanamycin implant | 30 | ＜0.05 |
| 3(10) | The rifapentine sustained-release implant | 40 | ＜0.05 |
| 4(10) | The capreomycin sustained-release implant | 40 | ＜0.05 |
| 5(10) | Kanamycin and capreomycin injection | 70 | ＜0.01 |
| 6(10) | Rifapentine and capreomycin implant | 70 | ＜0.01 |
| 7(10) | Rifapentine and kanamycin and capreomycin implant | 90 | ＜0.001 |
The result shows, kanamycin (5mg/kg), rifapentine (5mg/kg) and the independent placement of capreomycin implant all have certain fungistatic effect, bacteriostasis rate is 30% to 40%, yet, effect when share with synergist obviously strengthens, effect is best when share with kanamycin, rifapentine and capreomycin three medicines, and bacteriostasis rate is 90%.Operation most convenient, easy.Good effect not only, toxic and side effects is little.
Same potentiation also sees capreomycin and rifampicin, rifamycin, rifapentine, utilizes the associating of cloth spit of fland, streptomycin, amikacin or amikacin.
The vivo bacteria corrosion action of test 6, drug combination and single medicine relatively
With the rat is subjects, with 2 * 10
5Individual tubercule bacillus is injected in its femur bone marrow intracavity, and week back grouping (10/group) also awards the sustained-release implant treatment that contains different pharmaceutical.Check inflammatory activity such as local redness subsequently, put to death animal after 30 days and get local bone marrow inspection bacterium.Result's (table 4) shows, streptomycin (10mg/kg) and the independent application of rifampicin (5mg/kg) implant all have certain controlling to imitate, first week beginning after treatment of local redness is obviously dwindled, the animal dead rate is 50% in 60 days, yet the animal dead rate only is 10% (sustained-release implant) and 20% (slow releasing injection) in 60 days of therapeutic alliance group.
Table 4
| Test group (n) | Suffered treatment | Animal dead rate (%) | The P value |
| 1(10) | Contrast | 100 | |
| 2(10) | The streptomycin sustained-release implant | 50 | |
| 3(10) | The rifampicin sustained-release implant | 50 | ＜0.05 |
| 4(10) | Rifampicin and streptomycin slow releasing injection | 20 | ＜0.01 |
| 5(10) | Rifampicin and streptomycin sustained-release implant | 10 | ＜0.01 |
Same potentiation also sees rifampicin, rifamycin, rifapentine or utilizes the cloth spit of fland and the combination of streptomycin, kanamycin, amikacin or amikacin.
Test 7, antituberculotics and synergist external potentiation
Get 2 * 10
5Individual tubercule bacillus is cultivated after 24 hours and handled 24 hours with same concentration (5ug/ml) different pharmaceutical, detects inhibitory rate of cell growth (%), the results are shown in Table 5
The potentiation (suppression ratio %) of table 5 different pharmaceutical associating
| Rifampicin | Isoniazid | Ofloxacin | Rifampicin+isoniazid | Rifampicin+ofloxacin | Isoniazid+ofloxacin | Rifampicin+isoniazid+ofloxacin |
| 30 | 42 | 48 | 66 | 68 | 72 | 94 |
Test 7 results and show, the independent application of used antituberculotic and synergist all has tangible bacteriostasis, but the effect of use in conjunction is for well, wherein the effect of three kinds of drug combinations best (P＜0.01).
Same potentiation also sees cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin and rifampicin, rifamycin, rifapentine, utilizes the associating of cloth spit of fland, streptomycin, amikacin, amikacin, isoniazid, pyrazinamide, ethambutol or sodium aminosalicylate.
In a word, local placement and the single slow released antituberculotic agent of local injection all have the obvious suppression effect to the tulase growth, community's notable synergistic of two or more medicine, the particularly fungistatic effect of the more obvious enhancing antituberculotics of the associating of two or more antituberculotics and a kind of synergist.The therapeutical effect that is shown is all relevant with its local active drug concentration that obtains with potentiation.Therefore, the effective ingredient of slow releasing agent of the present invention is the combination of one or more antituberculotics and one or more antituberculotics synergists.
The medicine that contains above effective ingredient can be made into sustained-release micro-spheres, and then makes slow releasing injection and implant, serves as preferred with the suspensoid injectio that is combined to form with the special solvent that contains suspending agent wherein.
Slow releasing injection or sustained-release implant also can be further specified by following embodiment.Just the invention will be further described for the foregoing description and following examples, is not its content and use are imposed any restrictions.
(4) specific embodiment
Embodiment 1.
With 90,90 and 80mg polifeprosan (to carboxy phenyl propane (p-CPP): certain herbaceous plants with big flowers diacid (SA) is 20: 80) copolymer put into (first), (second) and (the third) three container respectively, add 100 milliliters of dichloromethane then in each, behind the dissolving mixing, add 10mg rifampicin, 10mg ofloxacin, 10mg rifampicin and 10mg ofloxacin respectively, shake up the back contains 10% rifampicin, 10% ofloxacin and 10% rifampicin and 10% ofloxacin with spray drying method for preparation injectable microsphere again.Then microsphere is suspended in the normal saline that contains 15% mannitol, makes corresponding suspension type slow releasing injection.The viscosity of injection is 300cp-600cp (20 ℃-30 ℃ time).The drug release time of this slow releasing injection in external normal saline is 15-20 days, is about 30-40 days at the subcutaneous drug release time of mice.
Embodiment 2.
The method step that is processed into slow releasing injection is identical with embodiment 1, but different is that contained tuberculosis effective ingredient and percentage by weight thereof are:
(a) rifampicin of 2-50%, rifamycin, rifapentine or utilize the combination of cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or the capreomycin of cloth spit of fland and 2-50%;
(b) combination of the cycloserine of the streptomycin of 2-50%, kanamycin, amikacin or amikacin and 2-50%, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin;
(c) combination of the cycloserine of the isoniazid of 2-50%, pyrazinamide, ethambutol or sodium aminosalicylate and 2-50%, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin;
(d) combination of the cycloserine of the rifampicin of 2-50% and pyrazinamide and 2-50%, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin;
(e) combination of different cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or the capreomycin with 2-50% of the ethionamide of 2-50% or rosickyite;
(f) combination of the cycloserine of the rifampicin of 2-50% and isoniazid and 2-50%, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin;
(g) combination of the isoniazid of the isoniazid of 2-50% and pyrazinamide and 2-50% and cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin; Or
(h) combination of the cycloserine of the isoniazid of the pyrazinamide of the isoniazid of 2-50% and 2-50% and 2-50% and 2-50%, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin.
Embodiment 3.
With 70mg molecular weight peak value 65000 polylactic acid (PLGA, 75: 25) put into (first), (second) and (the third) three container respectively, add 100 milliliters of dichloromethane then in each, behind the dissolving mixing, in three containers, add 30mg rifapentine, 30mg ofloxacin, 15mg rifapentine and 15mg ofloxacin respectively, shake up the back contains 30% rifapentine, 30% ofloxacin, 15% rifapentine and 15% ofloxacin with spray drying method for preparation injectable microsphere again.Dried microsphere is suspended in the normal saline that contains 1.5% sodium carboxymethyl cellulose, makes corresponding suspension type slow releasing injection.The viscosity of injection is 300cp-600cp (20 ℃-30 ℃ time).The drug release time of this slow releasing injection in external normal saline is 10-15 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 4
The method step that is processed into slow releasing injection is identical with embodiment 3, but different is that contained tuberculosis effective ingredient and percentage by weight thereof are: the rifampicin of 2-50%, rifamycin, rifapentine or utilize the combination of cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or the capreomycin of cloth spit of fland and 2-50%
Embodiment 5.
(EVAc) puts into container with the 70mg ethylene vinyl acetate copolymer, after adding 100 milliliters of dichloromethane dissolving mixings, add 20 milligrams of ciprofloxacins and 10 milligrams of isoniazids, shake up the back contains 20% ciprofloxacin and 10% isoniazid with spray drying method for preparation injectable microsphere again.Then microsphere is suspended in the injection that contains the 5-15% sorbitol, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 10-15 days, is about 25-35 days at the subcutaneous drug release time of mice.
Embodiment 6.
The method step that is processed into slow releasing injection is identical with embodiment 5, but different is that contained tuberculosis effective ingredient is: the combination of the cycloserine of the isoniazid of 2-50%, pyrazinamide, ethambutol or sodium aminosalicylate and 2-50%, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin.
Embodiment 7.
70mg polifeprosan (to carboxy phenyl propane (p-CPP): certain herbaceous plants with big flowers diacid (SA) is 20: 80) copolymer is put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 20mg pyrazinamide and 10mg Sparfloxacin, shake up the back contains 20% pyrazinamide and 10% Sparfloxacin with spray drying method for preparation injectable microsphere again.Microsphere is suspended in the normal saline that contains 1.5% sodium carboxymethyl cellulose and 0.5% Tween 80 then, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 10-15 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 8.
The method step that is processed into slow releasing injection is identical with embodiment 7, but different is that contained tuberculosis effective ingredient is: the combination of the cycloserine of the isoniazid of 2-50%, pyrazinamide, ethambutol or sodium aminosalicylate and 2-50%, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin.
Embodiment 9
70mg polifeprosan (to carboxy phenyl propane (p-CPP): certain herbaceous plants with big flowers diacid (SA) is 20: 80) copolymer is put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 15mg capreomycin and 15mg streptomycin, shake up the back again and contain 15% capreomycin and 15% streptomycin injectable microsphere with spray drying method for preparation.Then microsphere is suspended in the normal saline that contains 1.5% sodium carboxymethyl cellulose and 15% sorbitol and 0.2% Tween 80, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 10-15 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 10
The method step that is processed into slow releasing injection is identical with embodiment 9, but different is that contained tuberculosis effective ingredient is: the combination of the streptomycin of the cycloserine of 2-50%, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin and 5-40%, kanamycin, amikacin or amikacin.
Embodiment 11
70mg polifeprosan (to carboxy phenyl propane (p-CPP): certain herbaceous plants with big flowers diacid (SA) is 20: 80) copolymer is put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 10mg cycloserine and 10mg pyrazinamide and 10mg rifampicin, shake up the back contains 10% cycloserine and 10% pyrazinamide and 10% rifampicin with spray drying method for preparation injectable microsphere again.Then microsphere is made corresponding sustained-release implant through pressed disc method.The drug release time of this sustained-release implant in external normal saline is 10-15 days, is about 30-40 days at the subcutaneous drug release time of mice.
Embodiment 12
The method step that is processed into sustained-release implant is identical with embodiment 11, but different is that contained tuberculosis effective ingredient is:
The cycloserine of the isoniazid of 10-20%, pyrazinamide, ethambutol or sodium aminosalicylate and 10-20%, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin combination.
Embodiment 13
With 70mg molecular weight peak value 45000 polylactic acid (PLGA, 50: 50) put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 10mg ofloxacin and 10mg rifapentine and 10mg pyrazinamide, shake up the back contains 10% ofloxacin and 10% rifapentine and 10% pyrazinamide with spray drying method for preparation injectable microsphere again.Then microsphere is made corresponding sustained-release implant through pressed disc method.The drug release time of this sustained-release implant in external normal saline is 15-25 days, is about 35-50 days at the subcutaneous drug release time of mice.
Embodiment 14
The method step that is processed into sustained-release implant is identical with embodiment 11,13, but different is that contained tuberculosis effective ingredient and percentage by weight are:
(a) rifampicin of the isoniazid of the cycloserine of 5-40%, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin and 5-40%, pyrazinamide, ethambutol or sodium aminosalicylate and 5-40%, rifamycin, rifapentine or utilize the combination in cloth spit of fland;
(b) rifampicin of 5-40%, rifamycin, rifapentine or utilize ethionamide or the different combination of rosickyite of cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin and the 5-40% of cloth spit of fland and 5-40%;
(c) combination of the cycloserine of the streptomycin of the isoniazid of 5-40%, pyrazinamide, ethambutol or sodium aminosalicylate and 5-40%, kanamycin, amikacin or amikacin and 5-40%, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin; Or
(d) rifampicin of 5-40%, rifamycin, rifapentine or utilize ethionamide or the different combination of rosickyite of cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin and the 5-40% of cloth spit of fland and 5-40%.
Embodiment 15
The method step that is processed into slow releasing agent is identical with embodiment 1-14, but different is used slow-release auxiliary material is one of following or its combination:
A) the molecular weight peak value is the polylactic acid (PLA) of 10000-30000,30000-60000,60000-100000 or 100000-150000;
B) the molecular weight peak value is the polyglycolic acid of 10000-30000,30000-60000,60000-100000 or 100000-150000 and the copolymer of hydroxyacetic acid (PLGA), and wherein, the ratio of polyglycolic acid and hydroxyacetic acid is 50-95: 50-50;
C) ethylene vinyl acetate copolymer (EVAc);
D) 10: 90,20: 80,30: 70,40: 60,50: 50 or 60: 40 to carboxy phenyl propane (p-CPP): certain herbaceous plants with big flowers diacid (SA) copolymer (polifeprosan);
E) bis-fatty acid and decanedioic acid copolymer;
F) poly-(erucic acid dimer-decanedioic acid) copolymer;
G) poly-(fumaric acid-decanedioic acid) copolymer;
H) xylitol, oligosaccharide, chrondroitin, chitin, potassium salt, sodium salt, hyaluronic acid, collagen protein, gelatin or white tempera.
Embodiment 16
The method step that is processed into slow releasing injection is identical with embodiment 1-10, but different is used suspending agent is respectively one of following or its combination:
A) 0.5-3.0% carboxymethyl cellulose (sodium);
B) 5-15% mannitol;
C) 5-15% sorbitol;
D) 0.1-1.5% surfactant;
E) 0.1-0.5% polysorbas20;
F) (iodine) glycerol, simethicone, propylene glycol or carbomer;
G) 0.5-5% sodium carboxymethyl cellulose+0.1-0.5% soil temperature 80;
H) 5-20% mannitol+0.1-0.5% soil temperature 80; Or
I) 0.5-5% sodium carboxymethyl cellulose+5-20% sorbitol+0.1-0.5% soil temperature 80.
Above embodiment only is used for explanation, and is not limitation application of the present invention.
The present invention disclosed and the protection the content see claim.
Claims (10)
1. slow released compound antituberculotic preparation that contains synergist, it is characterized in that this medicinal slow release agent contains slow-release auxiliary material and antituberculotics and its synergist, this agent tuberculose focus local place or inject this agent can with anti-tuberculosis drugs and or synergist discharge in the tuberculose focus local slow, when effectively obtaining and keeping local active drug concentration, reduce its general toxicity, make things convenient for medication, increase medication effect.
2. the slow released antituberculotic preparation according to claim 1 is characterized in that this slow released antituberculotic preparation is a slow releasing injection, is grouped into by following one-tenth:
(A) sustained-release micro-spheres comprises:
The sick effective ingredient 1-70% of tuberculosis
Slow-release auxiliary material 30-99%
Suspending agent 0.0-30%
More than be weight percentage
With
(B) solvent is for common solvent or contain the special solvent of suspending agent.
Wherein,
The sick effective ingredient of tuberculosis is antituberculotics and antituberculotics synergist;
Slow-release auxiliary material is selected from one of following or its combination:
A) polylactic acid;
B) copolymer of polyglycolic acid and hydroxyacetic acid;
C) polifeprosan;
D) ethylene vinyl acetate copolymer;
E) bis-fatty acid and decanedioic acid copolymer;
F) poly-(erucic acid dimer-decanedioic acid) copolymer;
G) poly-(fumaric acid-decanedioic acid) copolymer;
H) xylitol, oligosaccharide, chrondroitin, chitin, potassium salt, sodium salt, hyaluronic acid, collagen protein, gelatin or white tempera.
The viscosity of suspending agent is 100cp-3000cp (20 ℃-30 ℃ time), is selected from one of sodium carboxymethyl cellulose, iodine glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, soil temperature 20, soil temperature 40 and soil temperature 80 or its combination.
3. the tuberculosis slow releasing injection according to claim 2, the antituberculotics that it is characterized in that the tuberculosis slow releasing injection be rifampicin, rifamycin, rifapentine, utilize one of cloth spit of fland, isoniazid, pyrazinamide, ethambutol, sodium aminosalicylate, streptomycin, kanamycin, amikacin, amikacin (AMK), ethionamide, prothionamide or its combination.
4. the tuberculosis slow releasing injection according to claim 2 is characterized in that the antituberculotics synergist is selected from one of cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin, capreomycin or its combination.
5. the tuberculosis slow releasing injection according to claim 2 is characterized in that:
(a) rifampicin and or the combination of isoniazid and cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin;
(b) combination of streptomycin, kanamycin, amikacin or amikacin and cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin;
(c) combination of pyrazinamide, ethambutol or sodium aminosalicylate and cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin;
(d) combination of rifampicin and pyrazinamide and cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin;
(e) the different combination with cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin of ethionamide or rosickyite;
(f) rifamycin, rifapentine or utilize the different combination in cloth spit of fland and ethionamide or rosickyite;
(g) combination of isoniazid and pyrazinamide and cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin; Or
(h) combination of rifampicin and pyrazinamide and isoniazid and cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin.
It is one of following that used suspending agent is respectively:
A) 0.5-3.0% carboxymethyl cellulose (sodium);
B) 5-15% mannitol;
C) 5-15% sorbitol;
D) 0.1-1.5% surfactant;
E) 0.1-0.5% polysorbas20;
F) (iodine) glycerol, simethicone, propylene glycol or carbomer;
G) 0.5-5% sodium carboxymethyl cellulose+0.1-0.5% soil temperature 80;
H) 5-20% mannitol+0.1-0.5% soil temperature 80; Or
I) 0.5-5% sodium carboxymethyl cellulose+5-20% sorbitol+0.1-0.5% soil temperature 80.
6. the slow released antituberculotic preparation according to claim 1 is characterized in that this slow released antituberculotic preparation is a sustained-release implant, is grouped into by following one-tenth:
(1) the sick effective ingredient 1-70% of tuberculosis
(2) slow-release auxiliary material 30-99%
(3) suspending agent 0.0-30%
More than be weight percentage
7. the tuberculosis sustained-release implant according to claim 6 is characterized in that the tuberculosis effective ingredient of tuberculosis sustained-release implant and percentage by weight thereof are:
(a) rifampicin of 2-50%, rifamycin, rifapentine or utilize the combination of cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or the capreomycin of cloth spit of fland and 2-50%;
(b) combination of the cycloserine of the streptomycin of 2-50%, kanamycin, amikacin or amikacin and 2-50%, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin;
(c) combination of the cycloserine of the isoniazid of 2-50%, pyrazinamide, ethambutol or sodium aminosalicylate and 2-50%, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin;
(d) combination of the cycloserine of the rifampicin of 2-50% and pyrazinamide and 2-50%, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin;
(e) combination of different cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or the capreomycin with 2-50% of the ethionamide of 2-50% or rosickyite;
(f) combination of the cycloserine of the rifampicin of 2-50% and isoniazid and 2-50%, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin;
(g) combination of the isoniazid of the isoniazid of 2-50% and pyrazinamide and 2-50% and cycloserine, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin; Or
(h) combination of the cycloserine of the isoniazid of the pyrazinamide of the isoniazid of 2-50% and 2-50% and 2-50% and 2-50%, ofloxacin, ciprofloxacin, Sparfloxacin or capreomycin.
8. the tuberculosis sustained-release implant according to claim 6 is characterized in that slow-release auxiliary material is selected from one of following or its combination:
A) polylactic acid;
B) copolymer of polyglycolic acid and hydroxyacetic acid;
C) polifeprosan;
D) ethylene vinyl acetate copolymer;
E) bis-fatty acid and decanedioic acid copolymer;
F) poly-(erucic acid dimer-decanedioic acid) copolymer;
G) poly-(fumaric acid-decanedioic acid) copolymer;
H) xylitol, oligosaccharide, chrondroitin, chitin, potassium salt, sodium salt, hyaluronic acid, collagen protein, gelatin or white tempera.
9. described according to Claim 8 described tuberculosis sustained-release implant is characterized in that in the slow-release auxiliary material:
A) the molecular weight peak value of polylactic acid is selected from 10000-30000,300000-60000,60000-100000 or 100000-150000;
B) in the copolymer of polyglycolic acid and hydroxyacetic acid, the ratio of polyglycolic acid and hydroxyacetic acid is 50-95: 50-50, and the molecular weight peak value is 10000-30000,300000-60000,60000-100000 or 100000-150000;
C) in the polifeprosan, to carboxy phenyl propane: the certain herbaceous plants with big flowers diacid is 10: 90,20: 80,30: 70,40: 60,50: 50 or 60: 40.
10. according to claim 1,2 and 6 described institute's tuberculosis slow releasing preparation, it is characterized in that described slow-release auxiliary material and percentage by weight thereof are:
(1) PLA of 55-90%;
(2) PLGA of 50-90%;
(3) polifeprosan of 50-85%;
(4) bis-fatty acid of 55-90% and decanedioic acid copolymer; Or
(5) EVAc of 55-90%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006102003372A CN1857725A (en) | 2006-04-11 | 2006-04-11 | Slow released compound antituberculotic preparation containing synergist |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006102003372A CN1857725A (en) | 2006-04-11 | 2006-04-11 | Slow released compound antituberculotic preparation containing synergist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1857725A true CN1857725A (en) | 2006-11-08 |
Family
ID=37296713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006102003372A Pending CN1857725A (en) | 2006-04-11 | 2006-04-11 | Slow released compound antituberculotic preparation containing synergist |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1857725A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102670611A (en) * | 2011-03-07 | 2012-09-19 | 中国人民解放军第三〇九医院 | Vascular targeting embolism sustained release agent of triple compound microsphere for antituberculosis drug, preparation method and applications thereof |
| CN106581048A (en) * | 2016-12-07 | 2017-04-26 | 郑州郑先医药科技有限公司 | Western medicine composition for treating tuberculosis and preparation method thereof |
| WO2023207398A1 (en) * | 2022-04-29 | 2023-11-02 | 首都医科大学附属北京胸科医院 | Use of anti-idiopathic pulmonary fibrosis drug nintedanib in treatment of tuberculosis |
-
2006
- 2006-04-11 CN CNA2006102003372A patent/CN1857725A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102670611A (en) * | 2011-03-07 | 2012-09-19 | 中国人民解放军第三〇九医院 | Vascular targeting embolism sustained release agent of triple compound microsphere for antituberculosis drug, preparation method and applications thereof |
| CN106581048A (en) * | 2016-12-07 | 2017-04-26 | 郑州郑先医药科技有限公司 | Western medicine composition for treating tuberculosis and preparation method thereof |
| WO2023207398A1 (en) * | 2022-04-29 | 2023-11-02 | 首都医科大学附属北京胸科医院 | Use of anti-idiopathic pulmonary fibrosis drug nintedanib in treatment of tuberculosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1857280A (en) | Slow released compound antituberculotic preparation | |
| CN1857725A (en) | Slow released compound antituberculotic preparation containing synergist | |
| CN1868453A (en) | Slow-release injection contg. platinum compounds and cellulotoxic medicines | |
| CN1850035A (en) | Antibiotic slow-release preparation for local use | |
| CN1861052A (en) | Slow-releasing injection contg. platinum compound and cytotoxin type anticarcinogen | |
| CN1843331A (en) | Slow release formulation containing antibiotic and its uses | |
| CN1861053A (en) | Slow-releasing injection contg. platinum compounds and cytotoxin type anticarcinogen | |
| CN1857220A (en) | Slow released antituberculotic preparation | |
| CN1857714A (en) | Slow released antituberculotic preparation | |
| CN1857219A (en) | Slow released medicine prepn containing antituberculotic | |
| CN1883706A (en) | Topically applied sustained-release antibiotic preparation | |
| CN1850036A (en) | Slow-release preparation containing quinolones antibiotics | |
| CN1879604A (en) | An antibiotics-containing sustained releasing injection and application thereof | |
| CN1857724A (en) | Slow released preparation containing antituberculotic | |
| CN1857218A (en) | Slow released medicine containing antituberculotic | |
| CN1919172A (en) | Anticancer slow release agent of nimustine and its progression agent | |
| CN1875935A (en) | A sustained release anticancer agent containing clorfarabine and cytotoxic drug | |
| CN1887265A (en) | Slow released anticancer prepn | |
| CN1857284A (en) | Slow released aminoglycoside antituberculotic preparation | |
| CN1887268A (en) | Slow released anticancer injection | |
| CN101040843A (en) | Solid tumor resisting release agent including nimustine and the intensifier | |
| CN1957919A (en) | Controlled release agent of containing fluorouracil and synergist | |
| CN1850051A (en) | Loaded vascular inhibitor and cellulotoxic drug anticancer slow-release injection | |
| CN1887257A (en) | Anticancer medicine composition of platinum compound and clorfarabine | |
| CN1875937A (en) | A sustained release injection carrying clorfarabine and cytotoxic drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |